drugset
drugset / Trial / NCT05870917

A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

NCT05870917 ↗

Phase 2 Active not recruiting 20 enrolled Institute of Hematology & Blood Diseases Hospital, China
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based Regimen (Bortezomib, Lenalidomide and Dexamethasone) combined with CART-ASCT-CART2 in Chinese patients with newly diagnosed primary plasma cell leukemia.

Timeline

Start
2023-05-23
Primary completion
2026-06
Completion
2027-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule 1.3 mg/m2 Subcutaneous
Subject Dexamethasone Small molecule 40 mg —
Subject Lenalidomide Other / unclassified 25 mg Oral
Subject anti-BCMA CAR-T Cell therapy — Intravenous

Indications

plasma cell leukemia